266 related articles for article (PubMed ID: 24144477)
1. Comparison of the immune responses induced by soluble and particulate Plasmodium vivax circumsporozoite vaccine candidates formulated in AS01 in rhesus macaques.
Vanloubbeeck Y; Pichyangkul S; Bayat B; Yongvanitchit K; Bennett JW; Sattabongkot J; Schaecher K; Ockenhouse CF; Cohen J; Yadava A;
Vaccine; 2013 Dec; 31(52):6216-24. PubMed ID: 24144477
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of immune responses to a Plasmodium vivax CSP-based recombinant protein vaccine candidate in combination with second-generation adjuvants in mice.
Lumsden JM; Nurmukhambetova S; Klein JH; Sattabongkot J; Bennett JW; Bertholet S; Fox CB; Reed SG; Ockenhouse CF; Howard RF; Polhemus ME; Yadava A
Vaccine; 2012 May; 30(22):3311-9. PubMed ID: 22425788
[TBL] [Abstract][Full Text] [Related]
3. Immunological evaluation of two novel engineered Plasmodium vivax circumsporozoite proteins formulated with different human-compatible vaccine adjuvants in C57BL/6 mice.
Shabani SH; Zakeri S; Mortazavi Y; Mehrizi AA
Med Microbiol Immunol; 2019 Dec; 208(6):731-745. PubMed ID: 31025102
[TBL] [Abstract][Full Text] [Related]
4. A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites.
Yadava A; Sattabongkot J; Washington MA; Ware LA; Majam V; Zheng H; Kumar S; Ockenhouse CF
Infect Immun; 2007 Mar; 75(3):1177-85. PubMed ID: 17158893
[TBL] [Abstract][Full Text] [Related]
5. Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.
Bennett JW; Yadava A; Tosh D; Sattabongkot J; Komisar J; Ware LA; McCarthy WF; Cowden JJ; Regules J; Spring MD; Paolino K; Hartzell JD; Cummings JF; Richie TL; Lumsden J; Kamau E; Murphy J; Lee C; Parekh F; Birkett A; Cohen J; Ballou WR; Polhemus ME; Vanloubbeeck YF; Vekemans J; Ockenhouse CF
PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004423. PubMed ID: 26919472
[TBL] [Abstract][Full Text] [Related]
6. Antigenicity and immunogenicity of a novel chimeric peptide antigen based on the P. vivax circumsporozoite protein.
Céspedes N; Arévalo-Herrera M; Felger I; Reed S; Kajava AV; Corradin G; Herrera S
Vaccine; 2013 Oct; 31(42):4923-30. PubMed ID: 23954378
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the safety and immunogenicity in rhesus monkeys of a recombinant malaria vaccine for Plasmodium vivax with a synthetic Toll-like receptor 4 agonist formulated in an emulsion.
Lumsden JM; Pichyangkul S; Srichairatanakul U; Yongvanitchit K; Limsalakpetch A; Nurmukhambetova S; Klein J; Bertholet S; Vedvick TS; Reed SG; Sattabongkot J; Bennett JW; Polhemus ME; Ockenhouse CF; Howard RF; Yadava A
Infect Immun; 2011 Sep; 79(9):3492-500. PubMed ID: 21690242
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents.
Teixeira LH; Tararam CA; Lasaro MO; Camacho AG; Ersching J; Leal MT; Herrera S; Bruna-Romero O; Soares IS; Nussenzweig RS; Ertl HC; Nussenzweig V; Rodrigues MM
Infect Immun; 2014 Feb; 82(2):793-807. PubMed ID: 24478093
[TBL] [Abstract][Full Text] [Related]
10. Generation, characterization and immunogenicity of a novel chimeric recombinant protein based on Plasmodium vivax AMA-1 and MSP1
Rocha MV; Françoso KS; Lima LC; Camargo TM; Machado RLD; Costa FTM; Rénia L; Nosten F; Russell B; Rodrigues MM; Soares IS
Vaccine; 2017 Apr; 35(18):2463-2472. PubMed ID: 28341111
[TBL] [Abstract][Full Text] [Related]
11. Process development for the production of an E. coli produced clinical grade recombinant malaria vaccine for Plasmodium vivax.
Bell BA; Wood JF; Bansal R; Ragab H; Cargo J; Washington MA; Wood CL; Ware LA; Ockenhouse CF; Yadava A
Vaccine; 2009 Feb; 27(9):1448-53. PubMed ID: 19138714
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC).
Udhayakumar V; Saekhou A; Fang S; Jue D; Wohlhueter RM; Lal AA
Vaccine; 1998; 16(9-10):982-8. PubMed ID: 9682348
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity of recombinant proteins consisting of Plasmodium vivax circumsporozoite protein allelic variant-derived epitopes fused with Salmonella enterica Serovar Typhimurium flagellin.
Leal MT; Camacho AG; Teixeira LH; Bargieri DY; Soares IS; Tararam CA; Rodrigues MM
Clin Vaccine Immunol; 2013 Sep; 20(9):1418-25. PubMed ID: 23863502
[TBL] [Abstract][Full Text] [Related]
14. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG
Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527
[TBL] [Abstract][Full Text] [Related]
15. Protective efficacy of a Plasmodium vivax circumsporozoite protein-based vaccine in Aotus nancymaae is associated with antibodies to the repeat region.
Yadava A; Hall CE; Sullivan JS; Nace D; Williams T; Collins WE; Ockenhouse CF; Barnwell JW
PLoS Negl Trop Dis; 2014 Oct; 8(10):e3268. PubMed ID: 25329054
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the immune response to RTS,S/AS01 and RTS,S/AS02 adjuvanted vaccines: randomized, double-blind study in malaria-naïve adults.
Leroux-Roels G; Leroux-Roels I; Clement F; Ofori-Anyinam O; Lievens M; Jongert E; Moris P; Ballou WR; Cohen J
Hum Vaccin Immunother; 2014; 10(8):2211-9. PubMed ID: 25424924
[TBL] [Abstract][Full Text] [Related]
17. Long-lasting humoral and cellular immune responses elicited by immunization with recombinant chimeras of the Plasmodium vivax circumsporozoite protein.
Almeida AP; Dias MO; Vieira Cde A; Chávez-Olórtegui C; Gazzineli RT; Rodrigues MM; Fujiwara RT; Bruna-Romero O
Vaccine; 2014 Apr; 32(19):2181-7. PubMed ID: 24582631
[TBL] [Abstract][Full Text] [Related]
18. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
Janitzek CM; Matondo S; Thrane S; Nielsen MA; Kavishe R; Mwakalinga SB; Theander TG; Salanti A; Sander AF
Malar J; 2016 Nov; 15(1):545. PubMed ID: 27825348
[TBL] [Abstract][Full Text] [Related]
19. Induction of protective antibodies in Saimiri monkeys by immunization with a multiple antigen construct (MAC) containing the Plasmodium vivax circumsporozoite protein repeat region and a universal T helper epitope of tetanus toxin.
Yang C; Collins WE; Xiao L; Saekhou AM; Reed RC; Nelson CO; Hunter RL; Jue DL; Fang S; Wohlhueter RM; Udhayakumar V; Lal AA
Vaccine; 1997 Mar; 15(4):377-86. PubMed ID: 9141208
[TBL] [Abstract][Full Text] [Related]
20. Production of Plasmodium vivax enolase in Escherichia coli and its protective properties.
Zhang C; Gu Y; Tang J; Lu F; Cao Y; Zhou H; Zhu G; Cao J; Gao Q
Hum Vaccin Immunother; 2016 Nov; 12(11):2855-2861. PubMed ID: 27487171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
